Emerging studies suggest Retatru tide , a dual stimulator targeting both GLP-1 and GIP , appears to provide a significant development for obesity management . Early clinical trials have demonstrated substantial losses in visceral tissue, conceivably outperforming current obesity therapies . However , further study is necessary to fully assess its s